Skip to main content
Log in

Hyperthermic IP chemotherapy in ovarian cancer cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Lim SL, et al. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecologic Oncology : Feb 2019. Available from: URL: http://doi.org/10.1016/j.ygyno.2019.01.025

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hyperthermic IP chemotherapy in ovarian cancer cost effective. PharmacoEcon Outcomes News 822, 14 (2019). https://doi.org/10.1007/s40274-019-5666-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5666-3

Navigation